RxDoctor Payments Data

Timur Roytman, MD

Urology · Honolulu, HINPI 1952458176

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (29.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Teleflex LLC at 50.0% of the total. Among urology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,594in general payments, 2019–2025

Across 124 payments — averaging $174.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$11K
  • Intuitive Surgical$5K
  • Telix Pharmaceuticals$2K
  • Neotract Inc.$1K
  • Astellas Pharma US Inc$732
  • Johnson & Johnson$557
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$6,37530%
  • Speaking & faculty fees$5,70626%
  • Travel & lodging$2,34411%
  • Food & beverage$3,95218%
  • Education$3,21715%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,594 in reported general payments places this provider in the 95th percentile of 46 urology providers in Hawaii.

See all urology providers in Hawaii

Medicare billing

Part B allowed, 2024
$316,314
Medicare patients
1,022
Services billed
3,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide78$921,193
MyrbetriqMirabegron47$49,105
ProliaDenosumab22$37,027
Tamsulosin Hcl1,062$24,038
Finasteride312$7,186
Silodosin48$5,710
Dutasteride74$5,528
Methenamine Hippurate36$4,563
Tolterodine Tartrate ErTolterodine Tartrate32$3,969
Solifenacin Succinate38$2,591
Alfuzosin Hcl ErAlfuzosin Hcl65$2,398
Fesoterodine Fumarate ErFesoterodine Fumarate16$2,069
Potassium Citrate ErPotassium Citrate23$1,960
Oxybutynin Chloride ErOxybutynin Chloride46$1,711
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$732$970,298125 claims
AmgenProlia$37$37,02722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 46 urology providers in Hawaii.

Other urology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →